Antimicrobials Working Group Highlights Member Company Participation at the 28th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID)

WASHINGTON, April 20, 2018 /PRNewswire/ — The Antimicrobials Working Group (AWG) today announced that thirteen of its member companies will present data from their clinical and research programs at the annual meeting of the European Congress of Clinical Microbiology and Infectious Diseases (ECCMID 2018) to be held April 21 – 24 in Madrid, Spain.

ECCMID is an annual scientific meeting that brings together the leading experts in the fields of clinical microbiology, infectious disease and infection control from across the globe to present and discuss the latest developments in the laboratory and in the clinic to advance research in a wide array of infectious diseases.

“AWG is proud to share that data from our member companies covering a vast swath of infectious disease topics will be presented at ECCMID 2018,” said Jeffrey Stein, Ph.D., president and chief executive officer of Cidara Therapeutics and Chairman of the AWG. “Representatives from AWG companies will be participating in over 70 different oral sessions and poster presentations showcasing developments in innovative antifungal and antibacterial therapies, in addition to progress related to therapeutic antibodies, new diagnostic tools, and more.”

The following AWG member companies will be presenting at ECCMID 2018: Arsanis Inc. (NASDAQ: ASNS) , Amplyx Pharmaceuticals, Cidara Therapeutics, Inc. (NASDAQ: CDTX) , ContraFect Corporation (NASDAQ: CFRX) , Iterum Therapeutics Ltd., Melinta Therapeutics, Inc. (NASDAQ: MLNT) , Motif Bio plc (AIM/NASDAQ: MTFB) , Nabriva Therapeutics Plc (NASDAQ: NBRV) , Paratek Pharmaceuticals, Inc. (NASDAQ: PRTK) , SCYNEXIS, Inc. (NASDAQ: SCYX) , Spero Therapeutics, Inc. (NASDAQ: SPRO) , T2 Biosystems, Inc. (NASDAQ: TTOO) and Theravance Biopharma, Inc. (NASDAQ:TBPH) .

For more information on AWG member company presentations and access to specific abstracts, please visit: http://f839307073.nxcli.net/eccmid-2018/ .

About The Antimicrobials Working Group

AWG was founded in 2012 with the vision of utilizing collective power to improve the regulatory, investment, and commercial environment for emerging infectious disease companies. Today, AWG is comprised of seventeen antimicrobials and diagnostic device companies: Amplyx Pharmaceuticals, Aridis Pharmaceuticals, Arsanis Inc., Cidara Therapeutics Inc., ContraFect Corporation, Iterum Therapeutics Ltd., Melinta Therapeutics Inc., Motif Bio PLC, Nabriva Therapeutics US Inc., Paratek Pharmaceuticals Inc., SCYNEXIS Inc., Spero Therapeutics, Inc., T2 Biosystems Inc., Theravance Biopharma U.S. Inc., Viamet, Vical Incorporated, and Zavante Therapeutics Inc.

For more information, visit: www.antimicrobialsworkinggroup.org

About The Conafay Group

The Conafay Group, led by Stephen R. Conafay, Principal, is a life-sciences government relations firm based in Washington D.C. that serves as Washington counsel and coalition manager for AWG.

For more information, visit: www.conafaygroup.com

SOURCE Antimicrobials Working Group (AWG)

Related Links

http://f839307073.nxcli.net

Michael N. Dudley, Pharm.D.

President and Chief Executive Officer
Qpex Biopharma, Inc.

Dr. Dudley has over 30 years of experience in antiinfective drug research, development, and commercialization. In 2018, he co-founded Qpex Biopharma which raised $33M in Series A financing and acquired the preclinical infectious disease programs from The Medicines Company. He has overseen the development and regulatory approval of 3 antibiotics, most recently a beta-lactamase inhibitor combination product from a new chemical class (vaborbactam) discovered in the company laboratories. The antibiotic product Vabomere™ advanced from discovery to FDA approval in 2017 in less than 8 years. He lead the negotiation for multiple contracts from public-private partnerships (e.g., BARDA of the US Government; Innovative Medicines Initiative for the EU) for a combined total of over $190 million funding to advance antimicrobial agents in development in the US and Europe. Prior to co-founding Qpex, he was Chief Scientific Officer and co-founder of Rempex Pharmaceuticals that was acquired by the Medicines Company (MDCO) in 2013, where he remained as the co-leader of the Infectious Disease Business Unit of MDCO. Prior to Rempex, he held VP/SVP/CSO positions of increasing responsibility at the biotech companies Mpex Pharmaceuticals (acquired by Aptalis in 2011), Diversa Corporation, and Microcide Pharmaceuticals. Prior to his career in pharmaceutical industry, he held full-time academic appointments that included Professor of Pharmacy and Chairman of the Department of Pharmacy Practice at the University of Rhode Island College of Pharmacy (URI), and Adjunct Professor of Medicine, Brown University School of Medicine at Roger Williams Medical Center in Providence, RI. As an academic researcher, he conducted preclinical and clinical research in antibacterial, antifungal, and antiviral agents, including pioneering work on PK-PD approaches for several classes of antiinfectives. Dr. Dudley has published over 130 scientific papers and book chapters describing the evaluation and clinical use of antiinfective agents and treatment of infectious diseases. He has served as an invited speaker at several FDA and EMA workshops, international meetings on infectious diseases, and advisor to several companies. He has served as an Editor for the journal Antimicrobial Agents and Chemotherapy and numerous other editorial and advisory boards. He completed undergraduate work at Pepperdine University and his Doctor of Pharmacy (PharmD) from the University of California San Francisco (UCSF), completed at residency at UCSF, and a fellowship in infectious diseases at Hartford Hospital.

Related Links

René Russo, PharmD, BCPS

René Russo, PharmD, BCPS

Roger J. Pomerantz, M.D., F.A.C.P.

Christine Ann Miller

Graham G. Lumsden

Marco Taglietti, M.D.

Ankit Mahadevia

Jeffrey Stein, Ph.D.

Evan Loh, M.D.

Michael Dunne, M.D

Ciara Kennedy, Ph.D.

Ted Schroeder

Kevin Finney

Manos Perros, Ph.D.

David Roblin

Stephen Conafay

Christopher J. Burns, Ph.D.

Michael N. Dudley, Pharm.D.

Ramani Varanasi

Corey Fishman

Felix Faupel

Adrian Nivoliez